The clinical research firm Celerion and the Korean Drug Development Fund (KDDF) have formed a formal collaboration to provide drug development expertise and support for the drug-discovery and development industry in South Korea.

The agreement in the form of a Memorandum of Understanding (MOU) provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion's expertise in early clinical research and bioanalysis, as well as the global footprint of external partner sites. The collaboration will support a sharing of knowledge between KDDF and Celerion and will focus on developing ways to bring Korean drug discoveries to the global market. The MOU further enhances both organizations' ability to effectively apply principles of translational medicine to the development of innovative new drugs.

Celerion will support all programs with KDDF, from the recently announced business expansion within the Biomedical Research Institute at Seoul National University Hospital (SNUH), in South Korea.

Source: Celerion